{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T21:39:30Z","timestamp":1790199570579,"version":"4.1.0"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2022,2,23]],"date-time":"2022-02-23T00:00:00Z","timestamp":1645574400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010738","name":"Ablynx","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010738","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Sanofi-Genzyme"},{"DOI":"10.13039\/100007343","name":"Shire","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007343","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006396","name":"Alexion","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006396","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008322","name":"CSL Behring","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012112","name":"Sobi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012112","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,6,23]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:p>Thrombotic thrombocytopenic purpura (TTP) is a life-threatening disease that is caused by severe ADAMTS-13 deficiency. Immune-mediated TTP develops due to autoantibodies against ADAMTS-13, whereas congenital TTP is caused by mutations in the ADAMTS13 gene. Diagnostic possibilities and treatment options in TTP have emerged in recent years, which prompted the International Society on Thrombosis and Haemostasis (ISTH) to publish clinical practice guidelines for the diagnosis and treatment of TTP in 2020. In this article, the European Renal Best Practice Working Group endorsed the ISTH guidelines and emphasizes a number of considerations, including the importance of rapid ADAMTS-13 activity testing, the use of rituximab and anti-von Willebrand factor therapies such as caplacizumab, that enhance the clinical applicability of the guidelines in Europe.<\/jats:p>","DOI":"10.1093\/ndt\/gfac034","type":"journal-article","created":{"date-parts":[[2022,2,16]],"date-time":"2022-02-16T20:13:10Z","timestamp":1645042390000},"page":"1229-1234","source":"Crossref","is-referenced-by-count":17,"title":["European Renal Best Practice endorsement of guidelines for diagnosis and therapy of thrombotic thrombocytopaenic purpura published by the International Society on Thrombosis and Haemostasis"],"prefix":"10.1093","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6214-5008","authenticated-orcid":false,"given":"Kathrin","family":"Eller","sequence":"first","affiliation":[{"name":"Division of Nephrology, Medical University of Graz , Graz , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Knoebl","sequence":"additional","affiliation":[{"name":"Division of Haematology and Haemostasis, Department of Medicine I, Medical University of Vienna , Vienna , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sevcan A","family":"Bakkaloglu","sequence":"additional","affiliation":[{"name":"Department of Paediatric Nephrology, Gazi University, Faculty of Medicine , Ankara , Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan J","family":"Menne","sequence":"additional","affiliation":[{"name":"KRH Klinikum Mitte \u2013 Location Siloah , Hannover , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul T","family":"Brinkkoetter","sequence":"additional","affiliation":[{"name":"Department II of Internal Medicine and Centre for Molecular Medicine Cologne (CMMC), Faculty of Medicine and University Hospital of Cologne, University of Cologne , Cologne , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonie","family":"Grandt","sequence":"additional","affiliation":[{"name":"Department of Medicine III - Nephrology, Ordensklinikum Linz Elisabethinen , Linz , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula","family":"Thiem","sequence":"additional","affiliation":[{"name":"Department of Medicine III - Nephrology, Ordensklinikum Linz Elisabethinen , Linz , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Coppo","sequence":"additional","affiliation":[{"name":"Department of Haematology, Reference Centre for Thrombotic Microangiopathies, Saint-Antoine University Hospital, Assistance Publique-H\u00f4pitaux de Paris , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Scully","sequence":"additional","affiliation":[{"name":"Department of Haematology, University College London Hospitals , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4635-6291","authenticated-orcid":false,"given":"Maria C","family":"Haller","sequence":"additional","affiliation":[{"name":"Department of Medicine III - Nephrology, Ordensklinikum Linz Elisabethinen , Linz , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,2,23]]},"reference":[{"key":"2022062300080389100_bib1","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1111\/jth.15010","article-title":"ISTH guidelines for treatment of thrombotic thrombocytopenic purpura","volume":"18","author":"Zheng","year":"2020","journal-title":"J Thromb Haemost"},{"key":"2022062300080389100_bib2","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1111\/jth.15006","article-title":"ISTH guidelines for the diagnosis of thrombotic thrombocytopenic purpura","volume":"18","author":"Zheng","year":"2020","journal-title":"J Thromb Haemost"},{"key":"2022062300080389100_bib3","doi-asserted-by":"crossref","first-page":"17020","DOI":"10.1038\/nrdp.2017.20","article-title":"Thrombotic thrombocytopenic purpura","volume":"3","author":"Kremer Hovinga","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"2022062300080389100_bib4","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/jth.13571","article-title":"Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies","volume":"15","author":"Scully","year":"2017","journal-title":"J Thromb Haemost"},{"key":"2022062300080389100_bib5","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/rth2.12160","article-title":"Thrombotic thrombocytopenic purpura: toward targeted therapy and precision medicine","volume":"3","author":"Coppo","year":"2019","journal-title":"Res Pract Thromb Haemost"},{"key":"2022062300080389100_bib6","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1111\/j.1365-2141.2008.07107.x","article-title":"Relationship between ADAMTS13 activity in clinical remission and the risk of TTP relapse","volume":"141","author":"Jin","year":"2008","journal-title":"Br J Haematol"},{"key":"2022062300080389100_bib7","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1182\/blood.2019000954","article-title":"How targeted therapy disrupts the treatment paradigm for acquired TTP: the risks, benefits, and unknowns","volume":"134","author":"Mazepa","year":"2019","journal-title":"Blood"},{"key":"2022062300080389100_bib8","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1182\/blood-2014-01-550244","article-title":"Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura","volume":"124","author":"Hie","year":"2014","journal-title":"Blood"},{"key":"2022062300080389100_bib9","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1182\/blood-2018-04-840090","article-title":"Preemptive rituximab prevents long-term relapses in immune-mediated thrombotic thrombocytopenic purpura","volume":"132","author":"Jestin","year":"2018","journal-title":"Blood"},{"key":"2022062300080389100_bib10","doi-asserted-by":"crossref","first-page":"1076029618825309","DOI":"10.1177\/1076029618825309","article-title":"Comparison of the long-term remission of rituximab and conventional treatment for acquired thrombotic thrombocytopenic purpura: a systematic review and meta-analysis","volume":"25","author":"Owattanapanich","year":"2019","journal-title":"Clin Appl Thromb Hemost"},{"key":"2022062300080389100_bib11","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1182\/bloodadvances.2017008268","article-title":"Rituximab prophylaxis to prevent thrombotic thrombocytopenic purpura relapse: outcome and evaluation of dosing regimens","volume":"1","author":"Westwood","year":"2017","journal-title":"Blood Adv"},{"key":"2022062300080389100_bib12","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/jth.12114","article-title":"Rituximab for thrombotic thrombocytopenic purpura: benefit of early administration during acute episodes and use of prophylaxis to prevent relapse","volume":"11","author":"Westwood","year":"2013","journal-title":"J Thromb Haemost"},{"key":"2022062300080389100_bib13","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1505533","article-title":"Caplacizumab for acquired thrombotic thrombocytopenic purpura","volume":"374","author":"Peyvandi","year":"2016","journal-title":"N Engl J Med"},{"key":"2022062300080389100_bib14","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa1806311","article-title":"Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura","volume":"380","author":"Scully","year":"2019","journal-title":"N Engl J Med"},{"key":"2022062300080389100_bib15","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.ypmed.2010.08.005","article-title":"AGREE II: advancing guideline development, reporting, and evaluation in health care","volume":"51","author":"Brouwers","year":"2010","journal-title":"Prev Med"},{"key":"2022062300080389100_bib16","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.1016\/S2352-3026(17)30026-1","article-title":"Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study","volume":"4","author":"Bendapudi","year":"2017","journal-title":"Lancet Haematol"},{"key":"2022062300080389100_bib17","doi-asserted-by":"crossref","first-page":"e10208","DOI":"10.1371\/journal.pone.0010208","article-title":"Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience","volume":"5","author":"Coppo","year":"2010","journal-title":"PLoS One"},{"key":"2022062300080389100_bib18","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1182\/blood.2020009150","article-title":"Redefining outcomes in immune TTP: an international working group consensus report","volume":"137","author":"Cuker","year":"2021","journal-title":"Blood"},{"key":"2022062300080389100_bib19","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1182\/bloodadvances.2020001973","article-title":"Real-world data confirm the effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura","volume":"4","author":"Volker","year":"2020","journal-title":"Blood Adv"},{"key":"2022062300080389100_bib20","doi-asserted-by":"crossref","first-page":"rkaa074","DOI":"10.1093\/rap\/rkaa074","article-title":"Pregnancy outcomes following maternal treatment with rituximab prior to or during pregnancy: a case series","volume":"5","author":"Perrotta","year":"2021","journal-title":"Rheumatol Adv Pract"},{"key":"2022062300080389100_bib21","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1111\/bjh.17833","article-title":"First use of the anti-VWF nanobody caplacizumab to treat iTTP in pregnancy","volume":"196","author":"Kuhne","year":"2022","journal-title":"Br J Haematol"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article-pdf\/doi\/10.1093\/ndt\/gfac034\/43683261\/gfac034.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/37\/7\/1229\/44138417\/gfac034.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/37\/7\/1229\/44138417\/gfac034.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,23]],"date-time":"2022-06-23T00:08:51Z","timestamp":1655942931000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/37\/7\/1229\/6534932"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,23]]},"references-count":21,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,2,23]]},"published-print":{"date-parts":[[2022,6,23]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfac034","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,7]]},"published":{"date-parts":[[2022,2,23]]}}}